| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Positron-Emission Tomography | 33 | 2022 | 299 | 3.950 |
Why?
|
| Fluorodeoxyglucose F18 | 21 | 2022 | 144 | 2.520 |
Why?
|
| Nuclear Medicine | 3 | 2024 | 8 | 2.430 |
Why?
|
| Tomography, X-Ray Computed | 25 | 2017 | 2092 | 2.290 |
Why?
|
| Multimodal Imaging | 17 | 2019 | 112 | 2.220 |
Why?
|
| Radiopharmaceuticals | 16 | 2018 | 162 | 2.190 |
Why?
|
| Artificial Intelligence | 4 | 2024 | 243 | 2.080 |
Why?
|
| Radium | 6 | 2019 | 8 | 1.920 |
Why?
|
| Bone Neoplasms | 10 | 2019 | 420 | 1.710 |
Why?
|
| Positron Emission Tomography Computed Tomography | 7 | 2022 | 80 | 1.400 |
Why?
|
| Osteosarcoma | 3 | 2019 | 253 | 0.970 |
Why?
|
| Radioisotopes | 4 | 2019 | 38 | 0.800 |
Why?
|
| Magnetic Resonance Imaging | 9 | 2024 | 3556 | 0.780 |
Why?
|
| Fluorine Radioisotopes | 4 | 2018 | 11 | 0.750 |
Why?
|
| Referral and Consultation | 1 | 2024 | 541 | 0.700 |
Why?
|
| Radiology | 1 | 2021 | 106 | 0.680 |
Why?
|
| Alpha Particles | 1 | 2019 | 1 | 0.640 |
Why?
|
| Attitude of Health Personnel | 1 | 2024 | 663 | 0.620 |
Why?
|
| Whole Body Imaging | 2 | 2015 | 29 | 0.610 |
Why?
|
| Tumor Burden | 3 | 2016 | 230 | 0.610 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2024 | 729 | 0.600 |
Why?
|
| Bone Diseases | 1 | 2017 | 43 | 0.540 |
Why?
|
| Femoral Neoplasms | 1 | 2015 | 9 | 0.490 |
Why?
|
| Lymphoma | 2 | 2016 | 322 | 0.480 |
Why?
|
| Blood-Brain Barrier | 1 | 2015 | 142 | 0.450 |
Why?
|
| Radionuclide Imaging | 3 | 2023 | 149 | 0.410 |
Why?
|
| Humans | 50 | 2024 | 124725 | 0.410 |
Why?
|
| Electric Conductivity | 1 | 2011 | 87 | 0.370 |
Why?
|
| Peripheral Nervous System Neoplasms | 1 | 2011 | 12 | 0.360 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 3 | 2018 | 88 | 0.360 |
Why?
|
| Prognosis | 11 | 2019 | 4627 | 0.360 |
Why?
|
| Melanoma | 2 | 2015 | 835 | 0.350 |
Why?
|
| Neoplasm Staging | 9 | 2019 | 1251 | 0.350 |
Why?
|
| Bias | 2 | 2024 | 131 | 0.340 |
Why?
|
| Lymph Nodes | 4 | 2022 | 382 | 0.320 |
Why?
|
| Middle Aged | 22 | 2022 | 26797 | 0.300 |
Why?
|
| Aged | 21 | 2019 | 19764 | 0.290 |
Why?
|
| Skin Neoplasms | 1 | 2015 | 808 | 0.280 |
Why?
|
| Male | 23 | 2024 | 61269 | 0.280 |
Why?
|
| Reproducibility of Results | 6 | 2015 | 2877 | 0.270 |
Why?
|
| Brain Neoplasms | 1 | 2015 | 1212 | 0.250 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 352 | 0.250 |
Why?
|
| Esophageal Neoplasms | 4 | 2010 | 371 | 0.250 |
Why?
|
| Tomography, Emission-Computed | 2 | 2010 | 44 | 0.250 |
Why?
|
| Female | 24 | 2024 | 66569 | 0.240 |
Why?
|
| Breast Neoplasms | 7 | 2012 | 2511 | 0.230 |
Why?
|
| Space Perception | 1 | 2024 | 63 | 0.230 |
Why?
|
| Visual Perception | 1 | 2024 | 124 | 0.220 |
Why?
|
| Diagnostic Imaging | 2 | 2024 | 276 | 0.210 |
Why?
|
| Aged, 80 and over | 11 | 2016 | 6548 | 0.210 |
Why?
|
| Adult | 18 | 2024 | 29488 | 0.210 |
Why?
|
| Inflammatory Breast Neoplasms | 2 | 2013 | 4 | 0.210 |
Why?
|
| Radiometry | 1 | 2022 | 38 | 0.200 |
Why?
|
| Young Adult | 8 | 2024 | 9023 | 0.200 |
Why?
|
| Neoplasm Metastasis | 3 | 2015 | 669 | 0.200 |
Why?
|
| Social Determinants of Health | 1 | 2024 | 124 | 0.190 |
Why?
|
| Risk | 1 | 2024 | 755 | 0.190 |
Why?
|
| Adolescent | 7 | 2019 | 19284 | 0.190 |
Why?
|
| Graves Disease | 1 | 2021 | 16 | 0.190 |
Why?
|
| Thyroid Diseases | 1 | 2021 | 34 | 0.180 |
Why?
|
| Hospitals, Pediatric | 2 | 2015 | 771 | 0.170 |
Why?
|
| Prospective Studies | 4 | 2016 | 6147 | 0.170 |
Why?
|
| Treatment Outcome | 8 | 2019 | 12356 | 0.170 |
Why?
|
| Research Design | 2 | 2015 | 693 | 0.170 |
Why?
|
| Disease-Free Survival | 4 | 2015 | 873 | 0.170 |
Why?
|
| Lung Neoplasms | 2 | 2014 | 1659 | 0.160 |
Why?
|
| Precision Medicine | 1 | 2022 | 319 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2010 | 71 | 0.160 |
Why?
|
| Single Photon Emission Computed Tomography Computed Tomography | 1 | 2019 | 7 | 0.160 |
Why?
|
| Thyroid Neoplasms | 1 | 2021 | 190 | 0.160 |
Why?
|
| Retrospective Studies | 13 | 2016 | 16335 | 0.150 |
Why?
|
| Reference Values | 3 | 2015 | 711 | 0.150 |
Why?
|
| Machine Learning | 1 | 2020 | 250 | 0.140 |
Why?
|
| Sodium Fluoride | 1 | 2017 | 12 | 0.140 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1214 | 0.140 |
Why?
|
| Receptors, Somatomedin | 1 | 2016 | 25 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3716 | 0.130 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2015 | 1140 | 0.130 |
Why?
|
| Vaccination | 1 | 2022 | 955 | 0.130 |
Why?
|
| Paraproteinemias | 1 | 2016 | 17 | 0.130 |
Why?
|
| Stroke | 1 | 2024 | 986 | 0.130 |
Why?
|
| Tertiary Healthcare | 1 | 2015 | 21 | 0.130 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 1356 | 0.120 |
Why?
|
| Skeleton | 1 | 2015 | 5 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2016 | 54 | 0.120 |
Why?
|
| Sarcoma, Ewing | 1 | 2016 | 107 | 0.120 |
Why?
|
| Radiotherapy | 1 | 2016 | 135 | 0.120 |
Why?
|
| Image Processing, Computer-Assisted | 2 | 2011 | 580 | 0.120 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2015 | 58 | 0.120 |
Why?
|
| Biomarkers, Tumor | 2 | 2015 | 1486 | 0.120 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 1 | 2015 | 107 | 0.120 |
Why?
|
| Neoplasms | 3 | 2016 | 2788 | 0.120 |
Why?
|
| Permeability | 1 | 2015 | 122 | 0.120 |
Why?
|
| Acetabulum | 1 | 2014 | 16 | 0.120 |
Why?
|
| Quality Control | 2 | 2013 | 119 | 0.120 |
Why?
|
| Tissue Distribution | 1 | 2015 | 382 | 0.110 |
Why?
|
| Joint Diseases | 1 | 2014 | 33 | 0.110 |
Why?
|
| Tertiary Care Centers | 1 | 2015 | 235 | 0.110 |
Why?
|
| Patient Outcome Assessment | 1 | 2015 | 91 | 0.110 |
Why?
|
| Bone Marrow | 1 | 2016 | 324 | 0.110 |
Why?
|
| Survival Analysis | 2 | 2015 | 1499 | 0.110 |
Why?
|
| Sirolimus | 2 | 2016 | 226 | 0.110 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2016 | 430 | 0.110 |
Why?
|
| Neoadjuvant Therapy | 2 | 2013 | 337 | 0.110 |
Why?
|
| Liver Neoplasms | 2 | 2016 | 1313 | 0.110 |
Why?
|
| Adipose Tissue | 1 | 2016 | 461 | 0.110 |
Why?
|
| Bone and Bones | 1 | 2015 | 266 | 0.100 |
Why?
|
| Esophagogastric Junction | 2 | 2010 | 29 | 0.100 |
Why?
|
| Anus Neoplasms | 1 | 2012 | 38 | 0.100 |
Why?
|
| Odds Ratio | 1 | 2015 | 1259 | 0.100 |
Why?
|
| Breast Diseases | 1 | 2012 | 35 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2012 | 63 | 0.090 |
Why?
|
| Automation | 1 | 2011 | 63 | 0.090 |
Why?
|
| Lymphatic Metastasis | 3 | 2012 | 414 | 0.090 |
Why?
|
| CA-125 Antigen | 1 | 2010 | 15 | 0.090 |
Why?
|
| Phantoms, Imaging | 1 | 2011 | 134 | 0.090 |
Why?
|
| Colonography, Computed Tomographic | 1 | 2010 | 16 | 0.080 |
Why?
|
| Sensitivity and Specificity | 5 | 2014 | 2050 | 0.080 |
Why?
|
| Pancreatic Neoplasms | 1 | 2016 | 691 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2012 | 668 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2011 | 760 | 0.070 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2016 | 931 | 0.070 |
Why?
|
| Stomach Neoplasms | 2 | 2010 | 545 | 0.070 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2011 | 529 | 0.070 |
Why?
|
| Prostatic Neoplasms | 1 | 2016 | 1548 | 0.070 |
Why?
|
| Child | 3 | 2016 | 24383 | 0.070 |
Why?
|
| Ovarian Neoplasms | 1 | 2010 | 419 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2010 | 1023 | 0.060 |
Why?
|
| Diagnosis, Differential | 3 | 2016 | 1883 | 0.060 |
Why?
|
| Time Factors | 1 | 2015 | 6308 | 0.060 |
Why?
|
| Proof of Concept Study | 1 | 2024 | 29 | 0.060 |
Why?
|
| Colorectal Neoplasms | 1 | 2010 | 574 | 0.050 |
Why?
|
| False Positive Reactions | 2 | 2014 | 144 | 0.050 |
Why?
|
| Attention | 1 | 2024 | 200 | 0.050 |
Why?
|
| Brain Mapping | 1 | 2024 | 397 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2014 | 2156 | 0.050 |
Why?
|
| Iodine Radioisotopes | 1 | 2021 | 75 | 0.050 |
Why?
|
| Infant | 1 | 2015 | 12475 | 0.040 |
Why?
|
| Child, Preschool | 1 | 2015 | 14018 | 0.040 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 607 | 0.040 |
Why?
|
| Fluorides | 1 | 2018 | 18 | 0.040 |
Why?
|
| Multivariate Analysis | 2 | 2013 | 1435 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 1037 | 0.030 |
Why?
|
| Nucleocytoplasmic Transport Proteins | 1 | 2016 | 8 | 0.030 |
Why?
|
| Aging | 1 | 2024 | 1182 | 0.030 |
Why?
|
| Phosphatidylinositol 3-Kinase | 1 | 2016 | 25 | 0.030 |
Why?
|
| Copper-transporting ATPases | 1 | 2016 | 23 | 0.030 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2016 | 78 | 0.030 |
Why?
|
| Glycolysis | 1 | 2016 | 150 | 0.030 |
Why?
|
| Pyrazines | 1 | 2016 | 75 | 0.030 |
Why?
|
| Drug Synergism | 1 | 2016 | 228 | 0.030 |
Why?
|
| Protein Array Analysis | 1 | 2016 | 101 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2016 | 93 | 0.030 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 129 | 0.030 |
Why?
|
| Cation Transport Proteins | 1 | 2016 | 93 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2016 | 374 | 0.030 |
Why?
|
| Adenosine Triphosphatases | 1 | 2016 | 200 | 0.030 |
Why?
|
| Imidazoles | 1 | 2016 | 194 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2016 | 568 | 0.030 |
Why?
|
| Pyrroles | 1 | 2016 | 177 | 0.030 |
Why?
|
| STAT3 Transcription Factor | 1 | 2016 | 220 | 0.030 |
Why?
|
| Up-Regulation | 1 | 2016 | 862 | 0.030 |
Why?
|
| Pyrimidines | 1 | 2016 | 367 | 0.030 |
Why?
|
| Brain | 1 | 2024 | 2982 | 0.030 |
Why?
|
| Mastitis | 1 | 2012 | 3 | 0.020 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2016 | 505 | 0.020 |
Why?
|
| Lymphatic Irradiation | 1 | 2012 | 5 | 0.020 |
Why?
|
| Residual Volume | 1 | 2012 | 3 | 0.020 |
Why?
|
| Evidence-Based Medicine | 1 | 2016 | 634 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 717 | 0.020 |
Why?
|
| Axilla | 1 | 2012 | 38 | 0.020 |
Why?
|
| Mastectomy | 1 | 2012 | 64 | 0.020 |
Why?
|
| Granuloma | 1 | 2012 | 68 | 0.020 |
Why?
|
| Necrosis | 1 | 2012 | 208 | 0.020 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2011 | 54 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2012 | 126 | 0.020 |
Why?
|
| Survival | 1 | 2010 | 19 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2016 | 1018 | 0.020 |
Why?
|
| Lactation | 1 | 2012 | 192 | 0.020 |
Why?
|
| Breast | 1 | 2012 | 214 | 0.020 |
Why?
|
| Tomography, Spiral Computed | 1 | 2010 | 16 | 0.020 |
Why?
|
| Cell Count | 1 | 2010 | 252 | 0.020 |
Why?
|
| Postoperative Care | 1 | 2012 | 298 | 0.020 |
Why?
|
| Respiratory Mechanics | 1 | 2010 | 75 | 0.020 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2011 | 341 | 0.020 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2009 | 144 | 0.020 |
Why?
|
| Cell Line, Tumor | 1 | 2016 | 3335 | 0.020 |
Why?
|
| Radiography, Thoracic | 1 | 2010 | 152 | 0.020 |
Why?
|
| Artifacts | 1 | 2010 | 109 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2010 | 778 | 0.020 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2009 | 361 | 0.020 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 219 | 0.020 |
Why?
|
| Contrast Media | 1 | 2012 | 473 | 0.020 |
Why?
|
| Biopsy | 1 | 2012 | 1237 | 0.020 |
Why?
|
| Biomarkers | 1 | 2016 | 3067 | 0.020 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2010 | 370 | 0.020 |
Why?
|
| Incidence | 1 | 2014 | 3142 | 0.020 |
Why?
|
| Receptor, ErbB-2 | 1 | 2010 | 514 | 0.020 |
Why?
|
| Combined Modality Therapy | 1 | 2010 | 1233 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 3447 | 0.010 |
Why?
|
| Survival Rate | 1 | 2009 | 2047 | 0.010 |
Why?
|
| Algorithms | 1 | 2009 | 1622 | 0.010 |
Why?
|
| Inflammation | 1 | 2009 | 1431 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 4806 | 0.010 |
Why?
|
| Mice | 1 | 2016 | 17577 | 0.010 |
Why?
|
| United States | 1 | 2014 | 10899 | 0.010 |
Why?
|
| Animals | 1 | 2016 | 34024 | 0.010 |
Why?
|